RxDoctor Payments Data

Cathy Shrader, MD

Ophthalmology · Clinton, MDNPI 1174615934

Payments from drug & device makers

$4,154in general payments, 2019–2025

Across 157 payments — averaging $26.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$874
  • Sun Pharmaceutical Industries Inc.$501
  • Alcon$485
  • Bausch & Lomb Americas Inc.$414
  • Kala Pharmaceuticals, Inc.$408
  • Tarsus Pharmaceuticals, Inc.$340
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,154 in reported general payments places this provider in the 70th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$671,770
Medicare patients
1,816
Services billed
6,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine121$158,126
XiidraLifitegrast76$140,529
LumiganBimatoprost133$102,694
Cyclosporine54$28,876
CombiganBrimonidine Tartrate/Timolol47$23,765
XdemvyLotilaner11$21,239
Timolol Maleate199$18,087
Travoprost58$14,668
RocklatanNetarsudil Mesylat/Latanoprost19$13,340
SimbrinzaBrinzolamide/Brimonidine Tart27$9,870
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$9,569
Latanoprost562$8,471
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat284$5,836
Prednisolone Acetate119$5,755
Brimonidine Tartrate86$5,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$874$284,585301 claims
Bausch & Lomb Americas Inc.Xiidra$414$140,52976 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$340$21,23911 claims
Aerie Pharmaceuticals, Inc.Rocklatan$97$13,34019 claims
AlconSimbrinza$485$9,87027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →